Compare BIO-TECHNE Corp (TECH) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Western Digital Corp — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Western Digital Corp trades at $438.1 (market cap $151.09B). The key difference: Western Digital Corp is far larger — about 13.4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals.
| TECH | WDC | |
|---|---|---|
Market Cap | $11.24B | $151.09B |
Sector | Health | Technology |
52-Week High | $72.29 | $746.23 |
52-Week Low | $43.31 | $74.64 |
Enterprise Value | $11.32B | $150.56B |
Dividend Yield | 0.44% | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
WDC trades at $434.3, down 3.81% over 24 hours, with a bearish technical signal as it hovers near the pivot point of $440. The company has shown strong earnings beats in recent quarters, with Q2 2026 EPS of $3.56 surpassing the $3.31 estimate, and maintains robust profitability margins, including a net income margin of 72.95% for 2025. Revenue for 2025 was $9.52B, with a significant turnaround to net income of $1.86B from prior losses, indicating operational recovery amid high cloud demand.
The outlook is mixed, with analyst consensus strongly bullish (72.13% buy ratings) and a price target of $665.15 suggesting substantial upside, but risks include high valuation multiples like a P/E of 17.89 and EV/EBITDA of 29.99, competitive pressures in HDD storage, and recent post-earnings sell-offs due to margin concerns. Investors should weigh the growth potential from AI-driven storage demand against cyclical and valuation headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
